Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paul Glasziou is active.

Publication


Featured researches published by Paul Glasziou.


Medical Care | 2009

Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes.

Philip Clarke; Alison J. Hayes; Paul Glasziou; Russell S. Scott; John Simes; Anthony Keech

Objective:To examine whether index scores based on the EQ-5D, a 5-item generic health status measure, are an independent predictor of vascular events, other major complications and mortality in people with type 2 diabetes and to quantify the relationship between these scores and future survival. Subjects:Five-year cohort study involving 7348 patients with type 2 diabetes, aged between 50–75 years who had been recruited to the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study from Australia and New Zealand. Measures:Multivariate Cox proportional hazard regression models were used to estimate the hazard ratio associated with index scores derived from the EQ-5D on: (1) cardiovascular events (including coronary heart disease event, stroke, hospitalization for angina, or cardiovascular death); (2) other major diabetes-related complications (heart failure, amputation, renal dialysis, and lower extremity ulcer); and (3) death from any cause. Life table methods were used to derive expected survival for patients with different index scores. Results:After adjusting for standard risk factors, a 0.1 higher index score (derived from the UK algorithm) was associated with an additional 7% (95% CI: 4–11%) lower risk of vascular events, a 13% (95% CI: 9–17%) lower risk of complications, and up to 14% (95% CI: 8–19%) lower rate of all-cause mortality. Conclusions:Index scores derived from the EQ-5D are an independent predictor of the risk of mortality, future vascular events, and other complications in people with type 2 diabetes. This should be taken into account when extrapolating health outcomes such as quality-adjusted life years (QALYs).


Diabetes Care | 2008

Can Self-Rated Health Scores Be Used for Risk Prediction in Patients With Type 2 Diabetes?

Alison J. Hayes; Philip Clarke; Paul Glasziou; R. John Simes; Paul L. Drury; Anthony Keech


Archive | 2016

Waiting time Yes Yes No Yes Yes No Knowledge and skills Moderate Moderate Low Moderate Moderate Moderate

Les Irwig; Jonathan C. Craig; Paul Glasziou; Patrick M. Bossuyt


Archive | 2015

Simulating the unobserved and the slope conditional on the observed

Rafael Perera; Emily McFadden; Julie McLellan; Tom Lung; Philip Clarke; Teresa Pérez; Thomas Fanshawe; Andrew Dalton; Andrew Farmer; Paul Glasziou; Osamu Takahashi; John Stevens; Les Irwig; Jennifer Hirst; Sarah Stevens; Asuka Leslie; Sachiko Ohde; Gautam A. Deshpande; Kevin Y. Urayama; Brian Shine; Richard L. Stevens


Archive | 2015

Populations taking statins: study names and references

Rafael Perera; Emily McFadden; Julie McLellan; Tom Lung; Philip Clarke; Teresa Pérez; Thomas Fanshawe; Andrew Dalton; Andrew Farmer; Paul Glasziou; Osamu Takahashi; John Stevens; Les Irwig; Jennifer Hirst; Sarah Stevens; Asuka Leslie; Sachiko Ohde; Gautam A. Deshpande; Kevin Y. Urayama; Brian Shine; Richard L. Stevens


Archive | 2015

Sensitivity analyses in populations taking statins

Rafael Perera; Emily McFadden; Julie McLellan; Tom Lung; Philip Clarke; Teresa Pérez; Thomas Fanshawe; Andrew Dalton; Andrew Farmer; Paul Glasziou; Osamu Takahashi; John Stevens; Les Irwig; Jennifer Hirst; Sarah Stevens; Asuka Leslie; Sachiko Ohde; Gautam A. Deshpande; Kevin Y. Urayama; Brian Shine; Richard L. Stevens


Archive | 2015

Modelling progression of lipid levels

Rafael Perera; Emily McFadden; Julie McLellan; Tom Lung; Philip Clarke; Teresa Pérez; Thomas Fanshawe; Andrew Dalton; Andrew Farmer; Paul Glasziou; Osamu Takahashi; John Stevens; Les Irwig; Jennifer Hirst; Sarah Stevens; Asuka Leslie; Sachiko Ohde; Gautam A. Deshpande; Kevin Y. Urayama; Brian Shine; Richard L. Stevens


Archive | 2015

Extracted data from studies for populations not taking statins

Rafael Perera; Emily McFadden; Julie McLellan; Tom Lung; Philip Clarke; Teresa Pérez; Thomas Fanshawe; Andrew Dalton; Andrew Farmer; Paul Glasziou; Osamu Takahashi; John Stevens; Les Irwig; Jennifer Hirst; Sarah Stevens; Asuka Leslie; Sachiko Ohde; Gautam A. Deshpande; Kevin Y. Urayama; Brian Shine; Richard L. Stevens


Archive | 2015

Impact on risk scores of different approaches to lipid measurement

Rafael Perera; Emily McFadden; Julie McLellan; Tom Lung; Philip Clarke; Teresa Pérez; Thomas Fanshawe; Andrew Dalton; Andrew Farmer; Paul Glasziou; Osamu Takahashi; John Stevens; Les Irwig; Jennifer Hirst; Sarah Stevens; Asuka Leslie; Sachiko Ohde; Gautam A. Deshpande; Kevin Y. Urayama; Brian Shine; Richard L. Stevens


Archive | 2015

Meta-analysis of the effect of atorvastatin on serum lipid levels: sensitivity analysis and results from the network meta-analysis

Rafael Perera; Emily McFadden; Julie McLellan; Tom Lung; Philip Clarke; Teresa Pérez; Thomas Fanshawe; Andrew Dalton; Andrew Farmer; Paul Glasziou; Osamu Takahashi; John Stevens; Les Irwig; Jennifer Hirst; Sarah Stevens; Asuka Leslie; Sachiko Ohde; Gautam A. Deshpande; Kevin Y. Urayama; Brian Shine; Richard L. Stevens

Collaboration


Dive into the Paul Glasziou's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tom Lung

University of Sydney

View shared research outputs
Top Co-Authors

Avatar

Brian Shine

John Radcliffe Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge